[{"orgOrder":0,"company":"Yale Cancer Center","sponsor":"Enlivex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allocetra","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yale Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Yale Cancer Center \/ Yale Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Yale Cancer Center \/ Yale Cancer Center"}]

Find Clinical Drug Pipeline Developments & Deals by Yale Cancer Center

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was combined with PD1 checkpoint inhibition in a murine model of ov...

                          Brand Name : Allocetra

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          August 17, 2022

                          Lead Product(s) : Allocetra,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Enlivex Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank